These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
575 related articles for article (PubMed ID: 17208229)
1. Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin. Kohno H; Sakai T; Saito S; Okano K; Kitahara K Exp Eye Res; 2007 Mar; 84(3):569-76. PubMed ID: 17208229 [TBL] [Abstract][Full Text] [Related]
2. Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor α agonist fenofibrate. Osada M; Sakai T; Kuroyanagi K; Kohno H; Tsuneoka H Mol Vis; 2014; 20():1518-26. PubMed ID: 25489225 [TBL] [Abstract][Full Text] [Related]
3. Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. Liu W; Li WM; Gao C; Sun NL J Autoimmun; 2005 Dec; 25(4):258-63. PubMed ID: 16242301 [TBL] [Abstract][Full Text] [Related]
4. Protective effect of intravitreal administration of tresperimus, an immunosuppressive drug, on experimental autoimmune uveoretinitis. Bousquet E; Camelo S; Leroux les Jardins G; Goldenberg B; Naud MC; Besson-Lescure B; Lebreton L; Annat J; Behar-Cohen F; de Kozak Y Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5414-23. PubMed ID: 21666239 [TBL] [Abstract][Full Text] [Related]
5. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity. Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291 [TBL] [Abstract][Full Text] [Related]
6. The suppressive effect of triptolide on experimental autoimmune uveoretinitis by down-regulating Th1-type response. Wu Y; Wang Y; Zhong C; Li Y; Li X; Sun B Int Immunopharmacol; 2003 Oct; 3(10-11):1457-65. PubMed ID: 12946442 [TBL] [Abstract][Full Text] [Related]
8. Protective effect of intravitreal injection of vasoactive intestinal peptide-loaded liposomes on experimental autoimmune uveoretinitis. Camelo S; Lajavardi L; Bochot A; Goldenberg B; Naud MC; Brunel N; Lescure B; Klein C; Fattal E; Behar-Cohen F; de Kozak Y J Ocul Pharmacol Ther; 2009 Feb; 25(1):9-21. PubMed ID: 19232006 [TBL] [Abstract][Full Text] [Related]
9. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. de Kozak Y; Andrieux K; Villarroya H; Klein C; Thillaye-Goldenberg B; Naud MC; Garcia E; Couvreur P Eur J Immunol; 2004 Dec; 34(12):3702-12. PubMed ID: 15517615 [TBL] [Abstract][Full Text] [Related]
10. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Zhang R; He R; Qian J; Guo J; Xue K; Yuan YF Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3575-82. PubMed ID: 20164461 [TBL] [Abstract][Full Text] [Related]
11. Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. Harry R; Gegg M; Hankey D; Zambarakji H; Pryce G; Baker D; Calder V; Adamson P; Greenwood J J Immunol; 2005 Feb; 174(4):2327-2335. PubMed ID: 15699169 [TBL] [Abstract][Full Text] [Related]
12. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Youssef S; Stüve O; Patarroyo JC; Ruiz PJ; Radosevich JL; Hur EM; Bravo M; Mitchell DJ; Sobel RA; Steinman L; Zamvil SS Nature; 2002 Nov; 420(6911):78-84. PubMed ID: 12422218 [TBL] [Abstract][Full Text] [Related]
13. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. Caspi RR; Roberge FG; McAllister CG; el-Saied M; Kuwabara T; Gery I; Hanna E; Nussenblatt RB J Immunol; 1986 Feb; 136(3):928-33. PubMed ID: 2416842 [TBL] [Abstract][Full Text] [Related]
14. Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. Sakai T; Kohno H; Ishihara T; Higaki M; Saito S; Matsushima M; Mizushima Y; Kitahara K Exp Eye Res; 2006 Apr; 82(4):657-63. PubMed ID: 16360654 [TBL] [Abstract][Full Text] [Related]
15. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. Kurose S; Ikeda E; Tokiwa M; Hikita N; Mochizuki M Exp Eye Res; 2000 Jan; 70(1):7-15. PubMed ID: 10644416 [TBL] [Abstract][Full Text] [Related]
16. Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice. Iwata D; Kitaichi N; Miyazaki A; Iwabuchi K; Yoshida K; Namba K; Ozaki M; Ohno S; Umezawa K; Yamashita K; Todo S; Ishida S; Onoé K Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2077-84. PubMed ID: 19907030 [TBL] [Abstract][Full Text] [Related]
17. Resident and infiltrating immune cells in the uveal tract in the early and late stages of experimental autoimmune uveoretinitis. Butler TL; McMenamin PG Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2195-210. PubMed ID: 8843906 [TBL] [Abstract][Full Text] [Related]